NEW YORK, Oct. 11 – Xtrana has been issued a US patent for a family of its nucleic acid extraction matrices, the company said on Wednesday.

The patent, numbered 6,291,166 and entitled "Nucleic Acid Archiving,” represents “the foundation technologies” for Xtrana products, according to a company statement.

The matrices, called Xtra Bind, capture and stabilize DNA and RNA and facilitate enzymatic manipulation of the nucleic acid, which Xtrana says results in “an extremely rapid and efficient extraction protocol.”

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.